|
Bloodwise (previously known as Leukaemia & Lymphoma Research) is the one of many charities in the UK exclusively dedicated to funding research into all blood cancers including leukaemia, lymphoma and myeloma. Bloodwise's vision is to beat blood cancers. They invest money into blood cancer research throughout the UK to ensure that all patients have their disease diagnosed early and accurately, receive personal, targeted treatments which are effective and have minimal side effects in order to beat or manage their cancer. ==History== Bloodwise was originally set up in 1960 as the Leukaemia Research Fund. The charity was started by the Eastwood family from Middlesbrough who began raising money following the death of their 6-year-old daughter Susan. Since its foundation in 1960, Bloodwise has invested over £500 in a number of different research projects which have helped improve understanding, diagnosis and treatment of blood cancers. In 1960 children diagnosed with leukaemia had a very poor chance of survival and Susan’s parents were determined to make something positive come from their personal tragedy, so they started fundraising for research that would find a cure for leukaemia. Since then the charity has expanded to include over 150 branches. The research funded by the charity has enabled more people than ever before to survive blood cancer. The survival rate for the most common form of childhood leukaemia has increased to over 90%, and for adults the survival rate is now as high as 70-80% for some forms of blood cancer. In 2011 the charity launched a Trials Acceleration Programme (TAP) to enable quicker and greater access to new treatments which has subsequently received government recognition as a model of good practice. This programme aims to make the process of clinical trials quicker and easier within the UK. TAP links 13 treatment centres around the UK coordinated by a central hub in Birmingham to set up more clinical trials in blood cancer. Because of this geographical spread, it means 20 million people in the UK could have access to the very latest promising blood cancer treatments, if they needed it. Until 2015, 16 new clinical trials have either been opened or approved thanks to TAP. A genetic study by a group of Newcastle University scientists published in the Journal of Clinical Oncology found that another research project funded by Bloodwise had reduced chances of a rare subtype of childhood leukaemia returning by 75%. In the financial year 2015, the charity has been able to invest £32.3 million in gross new grant commitments, one of the biggest commitments they've ever made (FY14: £23.2 million). A full list of the charity's current research projects can be found on the (National Cancer Research Institute’s International Cancer Research Portfolio ). 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Leukaemia & Lymphoma Research」の詳細全文を読む スポンサード リンク
|